biote (BTMD) Competitors $2.98 -0.02 (-0.67%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.05 +0.07 (+2.35%) As of 10/3/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. ERAS, MBX, OPT, IVA, ETON, ORKA, CMPS, CRVS, ZVRA, and ESPRShould you be buying biote stock or one of its competitors? The main competitors of biote include Erasca (ERAS), MBX Biosciences (MBX), Opthea (OPT), Inventiva (IVA), Eton Pharmaceuticals (ETON), Oruka Therapeutics (ORKA), COMPASS Pathways (CMPS), Corvus Pharmaceuticals (CRVS), Zevra Therapeutics (ZVRA), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. biote vs. Its Competitors Erasca MBX Biosciences Opthea Inventiva Eton Pharmaceuticals Oruka Therapeutics COMPASS Pathways Corvus Pharmaceuticals Zevra Therapeutics Esperion Therapeutics Erasca (NASDAQ:ERAS) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment. Which has more risk and volatility, ERAS or BTMD? Erasca has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, biote has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Do analysts prefer ERAS or BTMD? Erasca presently has a consensus target price of $3.71, indicating a potential upside of 53.48%. biote has a consensus target price of $6.00, indicating a potential upside of 101.34%. Given biote's higher possible upside, analysts clearly believe biote is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38biote 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger valuation and earnings, ERAS or BTMD? biote has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.45-5.38biote$197.19M0.75$3.16M$0.903.31 Do insiders & institutionals hold more shares of ERAS or BTMD? 67.8% of Erasca shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 14.4% of Erasca shares are held by company insiders. Comparatively, 24.0% of biote shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor ERAS or BTMD? In the previous week, Erasca had 3 more articles in the media than biote. MarketBeat recorded 3 mentions for Erasca and 0 mentions for biote. Erasca's average media sentiment score of 0.40 beat biote's score of 0.00 indicating that Erasca is being referred to more favorably in the media. Company Overall Sentiment Erasca Neutral biote Neutral Is ERAS or BTMD more profitable? biote has a net margin of 15.73% compared to Erasca's net margin of 0.00%. biote's return on equity of -21.00% beat Erasca's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -31.19% -26.34% biote 15.73%-21.00%18.26% Summarybiote beats Erasca on 9 of the 15 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.33M$10.99B$6.13B$10.58BDividend YieldN/A1.87%5.67%4.69%P/E Ratio3.3122.1186.9626.71Price / Sales0.7527.54605.32131.81Price / Cash3.8925.0337.9061.31Price / Book-1.073.4912.556.55Net Income$3.16M$212.45M$3.31B$277.50M7 Day Performance-0.33%5.11%4.28%2.42%1 Month Performance-13.87%1.56%6.90%8.63%1 Year Performance-41.91%-7.70%70.54%31.60% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.3511 of 5 stars$2.98-0.7%$6.00+101.3%-41.9%$147.33M$197.19M3.31194ERASErasca2.4986 of 5 stars$2.11+1.4%$3.71+76.0%-4.7%$590.03MN/A-4.69120News CoverageMBXMBX Biosciences0.3507 of 5 stars$17.94+2.5%N/AN/A$588.23MN/A-3.95N/AOPTOpthea0.4144 of 5 stars$3.41+7.2%$1.33-60.9%N/A$583.10M$30K0.008News CoveragePositive NewsGap UpHigh Trading VolumeIVAInventiva3.351 of 5 stars$5.87-3.0%$14.83+152.7%+248.9%$578.76M$9.95M0.00100Analyst ForecastHigh Trading VolumeETONEton Pharmaceuticals2.2253 of 5 stars$22.48+5.7%$29.67+32.0%+184.7%$570.41M$39.01M-140.5020Positive NewsHigh Trading VolumeORKAOruka Therapeutics3.0424 of 5 stars$19.29+26.9%$42.00+117.7%-22.3%$569.25MN/A-6.86N/AHigh Trading VolumeCMPSCOMPASS Pathways3.304 of 5 stars$5.87+1.2%$16.29+177.4%+3.5%$556.46MN/A-3.19120CRVSCorvus Pharmaceuticals1.4705 of 5 stars$7.28-1.5%$13.00+78.6%+27.5%$550.66MN/A-7.2130News CoveragePositive NewsZVRAZevra Therapeutics2.7203 of 5 stars$9.54-2.4%$24.00+151.6%+35.4%$548.44M$23.61M-45.4320Analyst DowngradeESPREsperion Therapeutics3.8606 of 5 stars$2.64-0.4%$7.00+165.2%+52.8%$534.30M$332.31M-5.39200News Coverage Related Companies and Tools Related Companies Erasca Alternatives MBX Biosciences Alternatives Opthea Alternatives Inventiva Alternatives Eton Pharmaceuticals Alternatives Oruka Therapeutics Alternatives COMPASS Pathways Alternatives Corvus Pharmaceuticals Alternatives Zevra Therapeutics Alternatives Esperion Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTMD Stock Alerts